This segment focuses on the development of innovative therapies for viral infectious diseases. Marinomed leverages its Carragelose® technology, derived from red algae, to create products that physically block viruses from entering cells, preventing infection. Research and development activities include preclinical studies and clinical trials to evaluate the efficacy and safety of Carragelose®-based nasal sprays and lozenges against various respiratory viruses, including influenza and coronaviruses. The therapeutic area covers a range of viral infections, with a focus on improving patient outcomes by reducing symptom severity and duration. Marinomed's market positioning is strengthened by its intellectual property portfolio and partnerships for global distribution. Future opportunities include expanding the application of Carragelose® to new viral targets and developing combination therapies.

This segment is dedicated to developing innovative treatments for immunological disorders, with a focus on allergic rhinitis and related conditions. Marinomed utilizes its Marinosolv® technology to enhance the solubility and bioavailability of poorly soluble drugs, enabling the development of more effective and targeted therapies. Research and development efforts include formulation optimization, preclinical studies, and clinical trials to assess the safety and efficacy of Marinosolv®-based products. The therapeutic area encompasses a range of immunological conditions, with a focus on improving patient quality of life by providing rapid and sustained symptom relief. Marinomed's market positioning is supported by its proprietary technology and strategic partnerships for product development and commercialization. Future opportunities include expanding the application of Marinosolv® to new therapeutic areas and developing personalized medicine approaches.